PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 30781783-3 2019 We used A549 cells that were exposed to transforming growth factor beta 1 (TGF-beta1), resulting in A549M cells with mesenchymal and drug resistant phenotype, and report that garcinol sensitized resistant cells with mesenchymal phenotype to erlotinib as well as cisplatin with significant decrease in their IC50 values. garcinol 175-183 transforming growth factor beta 1 Homo sapiens 40-73 30781783-3 2019 We used A549 cells that were exposed to transforming growth factor beta 1 (TGF-beta1), resulting in A549M cells with mesenchymal and drug resistant phenotype, and report that garcinol sensitized resistant cells with mesenchymal phenotype to erlotinib as well as cisplatin with significant decrease in their IC50 values. garcinol 175-183 transforming growth factor beta 1 Homo sapiens 75-84 31371781-0 2020 Garcinol inhibits esophageal cancer metastasis by suppressing the p300 and TGF-beta1 signaling pathways. garcinol 0-8 transforming growth factor beta 1 Homo sapiens 75-84 31371781-8 2020 We showed that garcinol treatment dose-dependently suppressed TGF-beta1-activated Smad and non-Smad pathway, inhibiting esophageal cancer cell metastasis. garcinol 15-23 transforming growth factor beta 1 Homo sapiens 62-71 31371781-10 2020 In conclusion, our study demonstrates that garcinol inhibits esophageal cancer metastasis in vitro and in vivo, which might be related to the suppression of p300 and TGF-beta1 signaling pathways, suggesting the therapeutic potential of Garcinol for metastatic tumors. garcinol 43-51 transforming growth factor beta 1 Homo sapiens 166-175 31371781-10 2020 In conclusion, our study demonstrates that garcinol inhibits esophageal cancer metastasis in vitro and in vivo, which might be related to the suppression of p300 and TGF-beta1 signaling pathways, suggesting the therapeutic potential of Garcinol for metastatic tumors. garcinol 236-244 transforming growth factor beta 1 Homo sapiens 166-175